Haploidentical hematopoietic stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC);Greffe de cellules-souches hématopoïétiques haplo-identiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Bulletin du Cancer

Volumn 103, Issue 11, 2016, Pages S229-S242

  Nguyen, Stéphanie ^a   Chalandon, Yves ^b   Lemarie, Claude ^c,d   Simon, Sophie ^e   Masson, Dominique ^e   Dhedin, Nathalie ^f   Suarez, Felipe ^g,h   Renaud, Barbara ⁱ   Charbonnier, Amandine ^j   Yafour, Nabil ^k,l   François, Sylvie ^m   Duléry, Rémy ^n,o   Blaise, Didier ^c   Yakoub Agha, Ibrahim ^p,q   Rubio, Marie Thérèse ^r,s  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c INSTITUT PAOLI CALMETTES   (France)

^d Centre d'Investigation Clinique   (France)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

^j AMIENS UNIVERSITY HOSPITAL   (France)

^k EHU   (Algeria)

^l UNIVERSITY OF ORAN   (Algeria)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ HÔPITAL SAINT ANTOINE   (France)

^o SORBONNE UNIVERSITÉ   (France)

^p LILLE UNIVERSITY HOSPITAL   (France)

^q UNIVERSITÉ DE LILLE   (France)

^r CHU NANCY BRABOIS   (France)

^s UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

Choice of donor; Conditioning regimens and indications; Haploidentical donor; Hematopoietic stem cell transplantation; Type of stem cell graft

Indexed keywords

ACUTE LEUKEMIA; ARTICLE; CELL THERAPY; DONOR SELECTION; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRACTICE GUIDELINE; AGE; BLOOD GROUP ABO SYSTEM; BONE MARROW TRANSPLANTATION; GENETICS; GRAFT VS HOST DISEASE; HAPLOIDY; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HODGKIN DISEASE; IMMUNOLOGY; LEUKEMIA; LYMPHOMA, NON-HODGKIN; PROCEDURES; SEX DIFFERENCE; STANDARDS; T LYMPHOCYTE; TRANSPLANTATION CONDITIONING;

BLOOD GROUP ABO SYSTEM;

ABO BLOOD-GROUP SYSTEM; AGE FACTORS; BONE MARROW TRANSPLANTATION; DONOR SELECTION; GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HODGKIN DISEASE; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; SEX FACTORS; SOCIETIES, MEDICAL; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 84999014779     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2016.09.007     Document Type: Article

References (51)

1. [1] Nguyen, S., Blaise, D., Bay, J.-O., Chevallier, P., Contentin, N., Dhédin, N., et al. Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2). Pathol Biol (Paris) 62:4 (2014), 185–189.
2. [2] Blaise, D., Nguyen, S., Bay, J.-O., Chevallier, P., Contentin, N., Dhédin, N., et al. Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1). Pathol Biol (Paris) 62:4 (2014), 180–184.
3. [3] Gladstone, D.E., Zachary, A.A., Fuchs, E.J., Luznik, L., Kasamon, Y.L., King, K.E., et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 19:4 (2013), 647–652.
4. [4] Yoshihara, S., Maruya, E., Taniguchi, K., Kaida, K., Kato, R., Inoue, T., et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 47:4 (2012), 508–515.
5. [5] Ciurea, S.O., de Lima, M., Cano, P., Korbling, M., Giralt, S., Shpall, E.J., et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88:8 (2009), 1019–1024.
6. [6] Ciurea, S.O., Thall, P.F., Wang, X., Wang, S.A., Hu, Y., Cano, P., et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118:22 (2011), 5957–5964.
7. [7] Takanashi, M., Atsuta, Y., Fujiwara, K., Kodo, H., Kai, S., Sato, H., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 116:15 (2010), 2839–2846.
8. [8] Cutler, C., Kim, H.T., Sun, L., Sese, D., Glotzbecker, B., Armand, P., et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 118:25 (2011), 6691–6697.
9. [9] Bramanti, S., Nocco, A., Mauro, E., Milone, G., Morabito, L., Sarina, B., et al. Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation: HLA Donor-specific antibodies and PEX. Transfusion (Paris) 56:5 (2016), 1096–1100.
10. [10] Anurathapan, U., Hongeng, S., Pakakasama, S., Sirachainan, N., Songdej, D., Chuansumrit, A., et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant 51:6 (2016), 813–818.
11. [11] Wang, Y., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Zhang, X.-H., Han, W., et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 119:5 (2013), 978–985.
12. [12] Kasamon, Y.L., Luznik, L., Leffell, M.S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16:4 (2010), 482–489.
13. [13] Ogawa, H., Ikegame, K., Yoshihara, S., Kawakami, M., Fujioka, T., Masuda, T., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 12:10 (2006), 1073–1084.
14. [14] Ichinohe, T., Uchiyama, T., Shimazaki, C., Matsuo, K., Tamaki, S., Hino, M., et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 104:12 (2004), 3821–3828.
15. [15] Wang, Y., Chang, Y.-J., Xu, L.-P., Liu, K.-Y., Liu, D.-H., Zhang, X.-H., et al. Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood 124:6 (2014), 843–850.
16. [16] Chang, Y.-J., Luznik, L., Fuchs, E.J., Huang, X.-J., How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. J Hematol Oncol J Hematol Oncol, 9, 2016, 35.
17. [17] Piemontese, S., Ciceri, F., Labopin, M., Bacigalupo, A., Huang, H., Santarone, S., et al. A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia 29:5 (2015), 1069–1075.
18. [18] Raiola, A.M., Dominietto, A., di Grazia, C., Lamparelli, T., Gualandi, F., Ibatici, A., et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 20:10 (2014), 1573–1579.
19. [19] Stern, M., Brand, R., de Witte, T., Sureda, A., Rocha, V., Passweg, J., et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant 8:10 (2008), 2149–2157.
20. [20] O'Donnell, P.V., Luznik, L., Jones, R.J., Vogelsang, G.B., Leffell, M.S., Phelps, M., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8:7 (2002), 377–386.
21. [21] Luznik, L., O'Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:6 (2008), 641–650.
22. [22] Brunstein, C.G., Fuchs, E.J., Carter, S.L., Karanes, C., Costa, L.J., Wu, J., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118:2 (2011), 282–288.
23. [23] Burroughs, L.M., O'Donnell, P.V., Sandmaier, B.M., Storer, B.E., Luznik, L., Symons, H.J., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14:11 (2008), 1279–1287.
24. [24] Raiola, A.M., Dominietto, A., Ghiso, A., Di Grazia, C., Lamparelli, T., Gualandi, F., et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19:1 (2013), 117–122.
25. [25] Ciurea, S.O., Zhang, M.-J., Bacigalupo, A.A., Bashey, A., Appelbaum, F.R., Aljitawi, O.S., et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126:8 (2015), 1033–1040.
26. [26] Sugita, J., Kawashima, N., Fujisaki, T., Kakihana, K., Ota, S., Matsuo, K., et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 21:9 (2015), 1646–1652.
27. [27] Raj, K., Pagliuca, A., Bradstock, K., Noriega, V., Potter, V., Streetly, M., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 20:6 (2014), 890–895.
28. [28] Castagna, L., Crocchiolo, R., Furst, S., Bramanti, S., El-Cheikh, J., Sarina, B., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 20:5 (2014), 724–729.
29. [29] Bradstock, K., Bilmon, I., Kwan, J., Blyth, E., Micklethwaite, K., Huang, G., et al. Influence of stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors. Biol Blood Marrow Transplant 21:9 (2015), 1641–1645.
30. [30] Ciurea, S.O., Mulanovich, V., Saliba, R.M., Bayraktar, U.D., Jiang, Y., Bassett, R., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18:12 (2012), 1835–1844.
31. [31] Bacigalupo, A., Dominietto, A., Ghiso, A., Di Grazia, C., Lamparelli, T., Gualandi, F., et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant 50:Suppl. 2 (2015), S37–S39.
32. [32] Solomon, S.R., Sizemore, C.A., Sanacore, M., Zhang, X., Brown, S., Holland, H.K., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 18:12 (2012), 1859–1866.
33. [33] Solomon, S.R., Sizemore, C.A., Sanacore, M., Zhang, X., Brown, S., Holland, H.K., et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 21:7 (2015), 1299–1307.
34. [34] Cieri, N., Greco, R., Crucitti, L., Morelli, M., Giglio, F., Levati, G., et al. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biol Blood Marrow Transplant 21:8 (2015), 1506–1514.
35. [35] Bashey, A., Zhang, X., Jackson, K., Brown, S., Ridgeway, M., Solh, M., et al. Comparison of outcomes of hematopoietic cell transplants from t-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant 22:1 (2016), 125–133.
36. [36] McCurdy, S.R., Kanakry, J.A., Showel, M.M., Tsai, H.-L., Bolaños-Meade, J., Rosner, G.L., et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 125:19 (2015), 3024–3031.
37. [37] Zoellner, A.-K., Fritsch, S., Prevalsek, D., Engel, N., Hubmann, M., Reibke, R., et al. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant 50:5 (2015), 679–684.
38. [38] Di Stasi, A., Milton, D.R., Poon, L.M., Hamdi, A., Rondon, G., Chen, J., et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 20:12 (2014), 1975–1981.
39. [39] Devillier, R., Bramanti, S., Fürst, S., Sarina, B., El-Cheikh, J., Crocchiolo, R., et al. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplant 51:2 (2016), 194–198.
40. [40] Ruggeri, A., Labopin, M., Sanz, G., Piemontese, S., Arcese, W., Bacigalupo, A., et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia 29:9 (2015), 1891–1900.
41. [41] Kasamon, Y.L., Bolaños-Meade, J., Prince, G.T., Tsai, H.-L., McCurdy, S.R., Kanakry, J.A., et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 33:28 (2015), 3152–3161.
42. [42] Castagna, L., Bramanti, S., Furst, S., Giordano, L., Crocchiolo, R., Sarina, B., et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant 49:12 (2014), 1475–1480.
43. [43] Kanate, A.S., Mussetti, A., Kharfan-Dabaja, M.A., Ahn, K.W., DiGilio, A., Beitinjaneh, A., et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127:7 (2016), 938–947.
44. [44] Bregante, S., Dominietto, A., Ghiso, A., Raiola, A.M., Gualandi, F., Varaldo, R., et al. Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors. Biol Blood Marrow Transplant 22:2 (2016), 324–329.
45. [45] Bolaños-Meade, J., Fuchs, E.J., Luznik, L., Lanzkron, S.M., Gamper, C.J., Jones, R.J., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120:22 (2012), 4285–4291.
46. [46] Clay, J., Kulasekararaj, A.G., Potter, V., Grimaldi, F., McLornan, D., Raj, K., et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant 20:11 (2014), 1711–1716.
47. [47] Esteves, I., Bonfim, C., Pasquini, R., Funke, V., Pereira, N.F., Rocha, V., et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant 50:5 (2015), 685–689.
48. [48] Gupta, N., Choudhary, D., Sharma, S.K., Khandelwal, V., Dhamija, M., Haploidentical hematopoietic SCT for acquired severe aplastic anemia using post-transplant high-dose CY. Bone Marrow Transplant 50:1 (2015), 155–156.
49. [49] Zeidan, A.M., Forde, P.M., Symons, H., Chen, A., Smith, B.D., Pratz, K., et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:3 (2014), 314–318.
50. [50] Ghiso, A., Raiola, A.M., Gualandi, F., Dominietto, A., Varaldo, R., Van Lint, M.T., et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant 50:1 (2015), 56–61.
51. [51] O'Donnell, P., Raj, K., Pagliuca, A., High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 21:1 (2015), 197–198.